Vaccines for Myeloma
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against myeloma and guarantee the finest results for our customers all over the world.
Myeloma
Multiple myeloma, also known as plasma cell myeloma, is a type of plasma cell cancer. Plasma cells are white blood cell that normally produces antibodies. Usually, no symptoms are observed initially. Bleeding, anemia, frequent infections, and bone pain may occur when advanced. Complications may include amyloidosis. Risk factors include family history, obesity, alcohol, radiation exposure, and certain chemicals. Multiple myeloma is considered to be treatable but incurable. Chemotherapy, thalidomide or lenalidomide and stem cell transplantation may alleviate the condition. Bisphosphonates and radiotherapy are sometimes used to relieve the pain of bone lesions.
Vaccine therapy can be used to maintain remission and prolong the survival of multiple myeloma, particularly when combined with other immunotherapies. Although malignant tumors rapidly evolve resistance to mutation-targeted therapy of signal pathway, cell surface antigens, which are targets of the immune system, tend to remain stable over time in multiple myeloma. Several promising vaccines are currently under study as possible treatments for multiple myeloma. A major area of research is the development of cancer vaccines to generate myeloma-specific immunity, which selectively targets malignant cells while minimizing toxicity to normal tissues. The key factors needed to develop an effective vaccine strategy include the identification of myeloma-associated antigens, the enhancement of antigen presentation, and reversing the immunosuppressive environment induced by the disease. In addition to the idiotypes on the immunoglobulins in multiple myeloma, a few but increasing numbers of immunogenic antigens have been found. These molecules are potential targets for vaccine-based cancer immunotherapy based on their tumor-related expression and their ability to elicit an immune response in the autologous host.
Our Vaccine Development Platforms for Myeloma
Antigen presenting cells (APCs) – Immune cells are stimulated to target myeloma cells
Allogenic stem cell based – Primed anti-myeloma stem cells from a vaccinated donor
- Non-Cell Based Vaccines
Protein/Peptide based – Full or shortened proteins unique to myeloma cells (e.g., Id protein, RHAMM, WT1, hTERT, MUC1, MAGE-C1, MAGE-A3, B7-H1, CD138, Hsp, PASA-1 protein)
Mutation based – Synthetic peptide base on genomic sequencing from individual patient tumor cells
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the vaccine development for myeloma. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
